"VSports" Lack of effect of ustekinumab in treatment of allergic contact dermatitis
- PMID: 21718332
- DOI: 10.1111/j.1600-0536.2011.01907.x
VSports最新版本 - Lack of effect of ustekinumab in treatment of allergic contact dermatitis
Abstract (V体育安卓版)
Background: Allergic contact dermatitis is a chronic inflammatory T cell mediated disease that can be recalcitrant to existing treatments. Ustekinumab is a monocloncal antibody blocking IL-12 and IL-23, shown to be effective and safe for patients with psoriasis. Despite both IL-12 and IL-23 involvement in contact allergy, the effect of Ustekinumab on allergic contact dermatitis has not been reported. VSports手机版.
Objectives: To evaluate the clinical effect of Ustekinumab in patients with allergic contact dermatitis. V体育安卓版.
Methods: A retrospective, case cohort study of patients with allergic contact dermatitis treated with Ustekinumab in our department. V体育ios版.
Results: Five patients had been treated with Ustekinumab for allergic contact dermatitis, with limited effect. VSports最新版本.
Conclusion: Our observation suggests that, although theoretically plausible, Ustekinumab does not seem to be a valuable therapeutic approach for chronic allergic contact dermatitis. V体育平台登录.
© 2011 John Wiley & Sons A/S.
"VSports在线直播" MeSH terms
- Actions (VSports最新版本)
- "VSports在线直播" Actions
- "VSports app下载" Actions
- V体育安卓版 - Actions
- "VSports在线直播" Actions
- VSports - Actions
- V体育安卓版 - Actions
Substances
- VSports注册入口 - Actions
- Actions (V体育2025版)
- "VSports注册入口" Actions
- Actions (VSports手机版)
LinkOut - more resources
Full Text Sources
